Open AccessIs the World Health Organization-recommended dose of pralidoxime effective in the treatment of organophosphorus poisoning? A randomized, double-blinded and placebo-controlled trial
Author(s) -
Sumaya Syed,
Showkat Ahmad Gurcoo,
Ayaz Khalid Farooqui,
Waqarul Nisa,
Khalid Sofi,
Tariq Wani
Publication year - 2015
Publication title -
saudi journal of anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.416
H-Index - 24
eISSN - 1658-354X
pISSN - 0975-3125
DOI - 10.4103/1658-354x.146306
Subject(s) - pralidoxime , medicine , placebo , intensive care medicine , intensive care unit , atropine , randomized controlled trial , anesthesia , alternative medicine , biochemistry , chemistry , pathology , acetylcholinesterase , enzyme
Organophosphorus poisoning (OPP) is a major global public health problem. Pralidoxime has been used in a complimentary role to atropine for the management of OPP. World Health Organization (WHO) recommends use of pralidoxime but studies regarding its role have been inconclusive, ranging from being ineffective to harmful or beneficial.